Single versus Double Autologous Stem-Cell Transplantation for Multiple Myeloma
The DOI matches its Crossref record; 17 of the 17 references it cites were found in a registry or an index.
Abstract
BACKGROUND: We conducted a randomized trial of the treatment of multiple myeloma with high-dose chemotherapy followed by either one or two successive autologous stem-cell transplantations. METHODS: At the time of diagnosis, 399 previously untreated patients under the age of 60 years were randomly assigned to receive a single or double transplant. RESULTS: A complete or a very good partial response was achieved by 42 percent of patients in the single-transplant group and 50 percent of patients in the double-transplant group (P=0.10). The probability of surviving event-free for seven years after the diagnosis was 10 percent in the single-transplant group and 20 percent in the double-transplant group (P=0.03). The estimated overall seven-year survival rate was 21 percent in the single-transplant group and 42 percent in the double-transplant group (P=0.01). Among patients who did not have a very good partial response within three months after one transplantation, the probability of surviving seven years was 11 percent in the single-transplant group and 43 percent in the double-transplant group (P<0.001). Four factors were significantly related to survival: base-line serum levels of beta2-microglobulin (P<0.01) and lactate dehydrogenase (P<0.01), age (P<0.05), and treatment group (P<0.01). CONCLUSIONS: As compared with a single autologous stem-cell transplantation after high-dose chemotherapy, double transplantation improves overall survival among patients with myeloma, especially those who do not have a very good partial response after undergoing one transplantation.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In earlier randomized trials, an improvement in OS was seen in two studies,132,133 but other studies failed to show such an improvement.134,135”
From Multiple myeloma: 2024 update on diagnosis, risk-stratification, and management (2024) · cites this paper as [132]
Citations
Cites
A Phase 2 Study of Bortezomib in Relapsed, Refractory Myeloma
Richardson, P. G., Barlogie, B., Berenson, J., Singhal, S., Jagannath, S., Irwin, D., Rajkumar, S. V., Srkalovic, G., Alsina, M., Alexanian, R., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa030288 · Cited by 2,632
Antitumor Activity of Thalidomide in Refractory Multiple Myeloma
Singhal, S., Mehta, J., Desikan, R., Ayers, D., Roberson, P., Eddlemon, P., Munshi, N., Anaissie, E., Wilson, C., Dhodapkar, M., et al. (1999) · New England Journal of Medicine · doi:10.1056/nejm199911183412102 · Cited by 2,575
Attal, M., Harousseau, J.-L., Stoppa, A.-M., Sotto, J.-J., Fuzibet, J.-G., Rossi, J.-F., Casassus, P., Maisonneuve, H., Facon, T., Ifrah, N., et al. (1996) · New England Journal of Medicine · doi:10.1056/nejm199607113350204 · Cited by 2,548
Self-citationHigh-Dose Chemotherapy with Hematopoietic Stem-Cell Rescue for Multiple Myeloma
Child, J. A., Morgan, G. J., Davies, F. E., Owen, R. G., Bell, S. E., Hawkins, K., Brown, J., Drayson, M. T., & Selby, P. J. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa022340 · Cited by 1,768
BladÉ, J., Samson, D., Reece, D., Apperley, J., BJÖrkstrand, B., Gahrton, G., Gertz, M., Giralt, S., Jagannath, S., Vesole, D., et al. (1998) · British Journal of Haematology · doi:10.1046/j.1365-2141.1998.00930.x · Cited by 1,519
Moreau, P. (2002) · Blood · doi:10.1182/blood.v99.3.731 · Cited by 564
Fermand, J.-P., Ravaud, P., Chevret, S., Divine, M., Leblond, V., Belanger, C., Macro, M., Pertuiset, E., Dreyfus, F., Mariette, X., et al. (1998) · Blood · doi:10.1182/blood.v92.9.3131 · Cited by 542
Total Therapy With Tandem Transplants for Newly Diagnosed Multiple Myeloma
Barlogie, B., Jagannath, S., Desikan, K. R., Mattox, S., Vesole, D., Siegel, D., Tricot, G., Munshi, N., Fassas, A., Singhal, S., et al. (1999) · Blood · doi:10.1182/blood.v93.1.55 · Cited by 472
(1998) · Journal of Clinical Oncology · doi:10.1200/jco.1998.16.12.3832 · Cited by 433
INTENSIVE TREATMENT OF MULTIPLE MYELOMA AND CRITERIA FOR COMPLETE REMISSION
Gore, M. E., Viner, C., Meldrum, M., Bell, J., Milan, S., Zuiable, A., Slevin, M., Selby, P. J., Clark, P. I., Millar, B., et al. (1989) · The Lancet · doi:10.1016/s0140-6736(89)91548-1 · Cited by 190
Research works printed but not linked: 7
- Barlogie B, 1991, Bone Marrow Transplant, 7, 71
- Fermand J-P, 1999, Blood, 94, 396a
- Blade J, 2001, Blood, 98, 815a
- Palumbo A, 2001, Blood, 98, 849a
- Fermand J-P, 2001, Blood, 98, 815a
- Richardson P, 2002, Blood, 100, 104a
- Sirohi B, 2002, Bone Marrow Transplant, 29, S12
Cited by
Items 501–600 of 987
Lee, S. R., Kim, S. J., Park, Y., Sung, H. J., Choi, C. W., & Kim, B. S. (2010) · The Korean Journal of Hematology · doi:10.5045/kjh.2010.45.3.183 · Cited by 13
“Although this result might be comparable with previous single ASCT studies in newly developed MM patients [15, 16], the improvement in the degree of response following bortezomib plus high-dose melphalan conditioning did not translate into an improvement in PFS in this study.”
ResultHematological malignancies: myeloma
Dimopoulos, M. A., Kastritis, E., & Anagnostopoulos, Α. (2006) · Annals of Oncology · doi:10.1093/annonc/mdl251 · Cited by 16
Phipps, C., Linenberger, M. L., Holmberg, L., Green, D., Becker, P. S., Connelly‐Smith, L. S., Klippel, Z. K., Burwick, N. R., Gopal, A. K., Bensinger, W., et al. (2015) · Bone Marrow Transplantation · doi:10.1038/bmt.2015.13 · Cited by 13
Lacativa, C. P. R., Lacativa, P. G. S., Garnica, M., Portugal, R. D., Schaffel, R., Dutra, H. S., Nogueira, C. M., Nucci, M., & Maiolino, Â. (2012) · Transfusion and Apheresis Science · doi:10.1016/j.transci.2012.06.013 · Cited by 14
Kawamura, K., Kikuchi, M., Terasako, K., Wada, H., Yamasaki, R., Ishihara, Y., Sakamoto, K., Ashizawa, M., Sato, M., Machishima, T., et al. (2013) · Transfusion and Apheresis Science · doi:10.1016/j.transci.2013.06.005 · Cited by 13
“For multiple myeloma patients, tandem autologous transplantation may be of limited benefit to patients who do not have a very good partial response after undergoing the first transplantation [15] and may not be suitable in the era of novel therapies such as bortezomib and lenalidomide.”
BackgroundSolitary bone plasmocytoma of the spine in an adolescent
Dumesnil, C., Schneider, P., Dolgopolov, I. S., Radi, S., Leluyer, B., & Vannier, J. (2005) · Pediatric Blood & Cancer · doi:10.1002/pbc.20493 · Cited by 13
“adriamycine, and dexamethasone) followed by melphalan-based high dose chemotherapy with autologous stem cell transplantation (ASCT) was effective [17,18].”
BackgroundRaje, N. S., Faiman, B. M., Harvey, R. D., Kurtin, S. E., Lonial, S., Kumar, S. K., Cohen, A. D., Conde, M. Á., Giralt, S., Recine, M. S., et al. (2014) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2014.04.011 · Cited by 13
Impaired PBPC collection in patients with myeloma after high-dose melphalan
Jansen, J., Thompson, J. M., Dugan, M. J., Wiemann, M. C., Hanks, S., Greenspan, A., & Akard, L. P. (2004) · Cytotherapy · doi:10.1080/14653240410005023 · Cited by 13
Quach, H., Joshua, D. E., Ho, J., Szer, J., Spencer, A. G., Harrison, S. J., Mollee, P. N., Roberts, A. W., Horvath, N., Talulikar, D., et al. (2015) · Internal Medicine Journal · doi:10.1111/imj.12640 · Cited by 17
Stem Cell Transplantation for Multiple Myeloma
Gasparetto, C. (2004) · Cancer Control · doi:10.1177/107327480401100218 · Cited by 14
Treatment of Newly Diagnosed Multiple Myeloma in Transplant-Eligible Patients
Kumar, S. K. (2011) · Current Hematologic Malignancy Reports · doi:10.1007/s11899-011-0083-0 · Cited by 15
“In a French trial (IFM94), event-free survival (20% vs 10%) and OS (42% vs 21%) at 7 years were significantly higher for the double-SCT arm [ 41 ].”
BackgroundKodama, T., Abe, M., Iida, S., Ozaki, S., Sakai, A., Sawamura, M., Shimazaki, C., Miyata, A., Wakayama, T., & Murakami, H. (2009) · Clinical Lymphoma & Myeloma · doi:10.3816/clm.2009.n.037 · Cited by 14
Bortezomib in Combination with Pegylated Liposomal Doxorubicin for the Treatment of Multiple Myeloma
Manochakian, R., Miller, K. C., & Chanan-Khan, A. A. (2007) · Clinical Lymphoma & Myeloma · doi:10.3816/clm.2007.n.001 · Cited by 13
Barlogie, B., Haessler, J., Pineda‐Roman, M., Anaissie, E. J., van Rhee, F., Kiwan, E. N., Steward, D., Gurley, J., Jenkins, B., & Crowley, J. J. (2008) · Cancer · doi:10.1002/cncr.23487 · Cited by 13
“Appreciating that multiple myeloma (MM) is a more hypoproliferative tumor than many other hematologic malignancies, the onset of complete remission (CR) occurs gradually over the course of 12 months to 18 months despite the use of high-dose therapy.(2,3) TT protocols used remission induction therapy, followed by melph…”
BackgroundDamon, L. E., Rugo, H. S., Tolaney, S. M., Navarro, W., Martin, T., Ries, C. A., Case, D. C., Ault, K. A., & LINKER, C. A. (2006) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2005.10.021 · Cited by 13
Emerging drugs in multiple myeloma
Ghobrial, I. M., Leleu, X. P., Hatjiharissi, E., Hideshima, T., Mitsiades, C. S., Schlossman, R. L., Anderson, K. C., & Richardson, P. G. G. (2007) · Expert Opinion on Emerging Drugs · doi:10.1517/14728214.12.1.155 · Cited by 14
“Based on this data, multiple other studies were performed to investigate the role of both single and tandem ASCT and allogeneic stem cell transplantation in MM [11,12].”
ResultTreatment of newly diagnosed multiple myeloma: advances in current therapy
Kumar, S. K. (2009) · Medical Oncology · doi:10.1007/s12032-009-9370-1 · Cited by 13
“The IFM94 trial showed a slight improvement in the combined CR and VGPR rate with double transplant (50 vs. 42%), but at 7 years, EFS (20 vs. 10%) and OS (42 vs. 21%) doubled with the second ASCT [ 46 ].”
Current Approaches to the Initial Treatment of Symptomatic Multiple Myeloma
Jasielec, J. K., & Jakubowiak, A. J. (2013) · International Journal of Hematologic Oncology · doi:10.2217/ijh.13.3 · Cited by 13
Nathwani, N., Larsen, J. T., & Kapoor, P. (2016) · Current Hematologic Malignancy Reports · doi:10.1007/s11899-016-0310-9 · Cited by 13
Montefusco, V., Corso, A., Galli, M., Ardoino, I., Pezzatti, S., Carniti, C., Patriarca, F. F., Gherlinzoni, F., Zambello, R., Sammassimo, S., et al. (2018) · British Journal of Haematology · doi:10.1111/bjh.16287 · Cited by 16
“At the time the trial was designed, depth of response endpoints were commonly used also in phase III trials (Attal et al., 2003).”
MethodKrummradt, F., Sauer, S., Pavel, P., Klein, E.-M., Schmitt, A., Kriegsmann, M., Jordan, K., Müller‐Tidow, C., Goldschmidt, H., Wuchter, P., et al. (2020) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2020.04.030 · Cited by 12
Garderet, L., Gras, L. A., Köster, L., Baaij, L. G. A., Hamad, N., D’Souza, A., Estrada‐Merly, N., Hari, P., Saber, W., Cowan, A. J., et al. (2024) · American Journal of Hematology · doi:10.1002/ajh.27451 · Cited by 17
Oncology: Treatment of Multiple Myeloma in the Targeted Therapy Era
Saad, A. A., Sharma, M. R., & Higa, G. M. (2009) · Annals of Pharmacotherapy · doi:10.1345/aph.1l428 · Cited by 13
Mainou, M., Madenidou, A., Liakos, A., Paschos, P., Karagiannis, T., Bekiari, E., Vlachaki, E., Wang, Z., Murad, M. H., Kumar, S. K., et al. (2017) · European Journal Of Haematology · doi:10.1111/ejh.12868 · Cited by 13
How best to use new therapies in multiple myeloma
Dingli, D., & Rajkumar, S. V. (2010) · Blood Reviews · doi:10.1016/j.blre.2010.03.001 · Cited by 12
“17,25 In contrast, other cytogenetic abnormalities, especially hyperdiploid myeloma and t(11;14) and a low PCLI imply a good prognosis and can be considered ‘standard risk disease’.”
BackgroundZappasodi, P., Nosari, A., Astori, C., Ciapanna, D., Bonfichi, M., Varettoni, M., Mangiacavalli, S., Morra, E., Lazzarino, M., & Corso, A. (2008) · Transfusion · doi:10.1111/j.1537-2995.2007.01621.x · Cited by 12
Haematopoietic stem cell transplantation: current status.
Kumar, L. (2007) · PubMed · Cited by 12
Gertz, M. A., Leung, N., Lacy, M. Q., & Dispenzieri, A. A. (2005) · Kidney International · doi:10.1111/j.1523-1755.2005.00559.x · Cited by 12
Current treatment options for myeloma
Terpos, E., Rahemtulla, A., & Dimopoulos, M. A. (2005) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.6.7.1127 · Cited by 14
“Unfortunately, the patients in the single transplant group received HDT with melphalan 140 mg/m2 and 8 Gy total body [42].”
MethodGojo, I., Meisenberg, B. R., Guo, C., Fassas, A., Murthy, A., Fenton, R., Takebe, N., Heyman, M., Philips, G., Cottler‐Fox, M., et al. (2005) · Bone Marrow Transplantation · doi:10.1038/sj.bmt.1705192 · Cited by 12
Multiple myeloma: the present and the future
Joshua, D. (2005) · The Medical Journal of Australia · doi:10.5694/j.1326-5377.2005.tb07079.x · Cited by 12
Evolving Paradigms in the Treatment of Newly Diagnosed Multiple Myeloma
Larocca, A., & Palumbo, A. P. (2011) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2011.0096 · Cited by 11
Garderet, L., Morris, C., Beksaç, M., Gahrton, G., Schönland, S. O., Yakoub‐Agha, I., & Hayden, P. J. (2020) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2020.04.016 · Cited by 11
Giebel, S., Sobczyk‐Kruszelnicka, M., Blamek, S., Saduś‐Wojciechowska, M., Najda, J., Czerw, T., Mendrek, W., Woźniak, G., Jochymek, B., Radwan, M., et al. (2020) · Bone Marrow Transplantation · doi:10.1038/s41409-020-01181-x · Cited by 11
Narsipur, N., Bulla, S., Yoo, C., Do, B., Tran, K., Gu, D., Zhong, L., & Wilson, L. (2021) · Journal of Managed Care & Specialty Pharmacy · doi:10.18553/jmcp.2021.27.12.1691 · Cited by 13
Jung, S., Koh, Y., Kim, M. K., Kim, J. S., Moon, J., Min, C., Yoon, D. H., Yoon, S. S., Lee, J., Hong, C. M., et al. (2025) · Blood Research · doi:10.1007/s44313-025-00055-9 · Cited by 15
Annunziata, M., Celentano, M., Pocali, B., D’Amico, M. R., Palmieri, S., Viola, A., Copia, C., Falco, C., Vecchio, L. D., & Ferrara, F. (2006) · Annals of Hematology · doi:10.1007/s00277-005-0058-0 · Cited by 11
Byrne, M. T., Wingard, J. R., & Moreb, J. S. (2013) · Transplantation Proceedings · doi:10.1016/j.transproceed.2013.03.054 · Cited by 11
Role of Hematopoietic Stem Cell Transplantation in Multiple Myeloma
Garcia, I. N. (2014) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2014.07.007 · Cited by 12
Autologous stem cell transplants in Jehovah's Witnesses
Brown, N. M., Kim, S. Y., & Ford, P. (2009) · Bone Marrow Transplantation · doi:10.1038/bmt.2009.43 · Cited by 11
Kortüm, K. M., Engelhardt, M. M., Rasche, L., Knop, S. T., & Einsele, H. (2013) · Der Internist · doi:10.1007/s00108-013-3336-2 · Cited by 12
Conventional therapy and approach to management
Rajkumar, S. V., & Kyle, R. A. (2005) · Best Practice & Research Clinical Haematology · doi:10.1016/j.beha.2005.01.011 · Cited by 13
Blocka, J., Hielscher, T., Goldschmidt, H., & Hillengaß, J. (2020) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2020.03.006 · Cited by 11
Mai, E. K., Miah, K., Bertsch, U., Dürig, J., Scheid, C., Weisel, K. C., Kunz, C., Munder, M., Lindemann, H., Merz, M., et al. (2020) · Leukemia · doi:10.1038/s41375-020-0976-9 · Cited by 11
Haas, P. S., Bauchmüller, K., Kühnemund, A., Finke, J., Ihorst, G., & Engelhardt, M. M. (2005) · Annals of Hematology · doi:10.1007/s00277-005-0040-x · Cited by 11
“sufficient response after first-line treatment [2].”
Evaluation and monitoring of response to therapy in multiple myeloma.
Rajkumar, S. V., & Dispenzieri, A. A. (2005) · PubMed · Cited by 13
Multiple myeloma – 2020 update on diagnosis and management
Charliński, G., & Jurczyszyn, A. J. (2020) · Nowotwory Journal of Oncology · doi:10.5603/njo.a2020.0035 · Cited by 10
Single versus tandem autologous stem cell transplantation in newly diagnosed multiple myeloma
Grieb, N., Oeser, A., Ferle, M., Hanke, F., Flossdorf, S., Sauer, S., Goldschmidt, H., Müller‐Tidow, C., Salwender, H.-J., Fenk, R. R., et al. (2024) · Bone Marrow Transplantation · doi:10.1038/s41409-024-02490-1 · Cited by 12
“However, most of the clinical trials that compared single with tandem ASCT were performed before the introduction of modern induction therapies, thus not taking into accont the impact of improved remissions before ASCT [8, 9].”
Treatment of a Jehovah's Witness using a transfusion-free autologous stem cell transplant protocol
Brown, N. M., Matthews, B. J., & Ford, P. (2006) · Community Oncology · doi:10.1016/s1548-5315(11)70948-2 · Cited by 10
Chen, A. I., Negrin, R. S., McMillan, A., Shizuru, J. A., Johnston, L., Lowsky, R., Miklos, D. B., Arai, S., Weng, W.-K., Laport, G. G., et al. (2011) · Bone Marrow Transplantation · doi:10.1038/bmt.2011.106 · Cited by 10
Role of Consolidation Therapy in Transplant Eligible Multiple Myeloma Patients
Cavo, M., Brioli, A., Tacchetti, P., Zannetti, B. A., Mancuso, K., & Zamagni, E. (2013) · Seminars in Oncology · doi:10.1053/j.seminoncol.2013.07.001 · Cited by 10
Samaras, P., Bargetzi, M. J., Betticher, D. C., Duchosal, M. A., Heim, D. A., Hess, U., Ketterer, N., Lerch, E., Matthes, T., Mey, U., et al. (2015) · Swiss Medical Weekly · doi:10.4414/smw.2015.14100 · Cited by 11
Thoennissen, G. B., Görlich, D., Bacher, U., Aufenberg, T., Hüsken, A.-C., Hansmeier, A., Evers, G., Mikesch, J., Fritz, F., Bokemeyer, C., et al. (2017) · Acta Haematologica · doi:10.1159/000463534 · Cited by 10
Chan, H. S. H., Phillips, M. J., Maganti, M. D., Farooki, S., Rodriguez, G. P., Masih‐Khan, E., Chen, C. I., Prica, A. A., Reece, D. E., Tiedemann, R. E., et al. (2018) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2017.12.009 · Cited by 10
Knowing the unknowns in high risk multiple myeloma
Derman, B. A., Kosuri, S., & Jakubowiak, A. J. (2021) · Blood Reviews · doi:10.1016/j.blre.2021.100887 · Cited by 11
Current status of autologous hematopoietic stem cell transplantation in myeloma
Mehta, J., & Singhal, S. (2008) · Bone Marrow Transplantation · doi:10.1038/bmt.2008.109 · Cited by 11
Sunami, K., Shinagawa, K., Sawamura, M., Sakai, A., Saburi, Y., Imamura, Y., Mizuno, I., Tamaki, S., Kamimura, T., Tsuda, H., et al. (2009) · International Journal of Hematology · doi:10.1007/s12185-009-0445-8 · Cited by 12
“However, the 5-year OS in our study was 66.5%, and it may be better than the OS of the single transplantation arm in IFM94 [ 24 ], MRCVII [14] and Bologna96 [25] (the median OS: 48, 54 and 65 months, respectively).”
BackgroundInfluentialIn pursuit of the allo-immune response in multiple myeloma: where do we go from here?
Cook, G., Bird, J. M., & Marks, D. I. (2008) · Bone Marrow Transplantation · doi:10.1038/bmt.2008.397 · Cited by 10
Cameron, G., Tantiworawit, A., Halpenny, M., Letcher, B., Berrigan, S., Hindmarsh, K., Giftakis, A., Fortier, J., O’Hoski, P., & Hogge, D. E. (2011) · Cytotherapy · doi:10.3109/14653249.2011.563293 · Cited by 10
Hematopoietic Stem and Progenitor Cell Mobilization in Mice
Hoggatt, J., Tate, T. A., & Pelus, L. M. (2014) · Methods in molecular biology · doi:10.1007/978-1-4939-1133-2_4 · Cited by 12
Management of Transplant-Eligible Patients with Newly Diagnosed Multiple Myeloma
Laubach, J. P., & Kumar, S. K. (2016) · Cancer treatment and research · doi:10.1007/978-3-319-40320-5_9 · Cited by 10
Long-term survival in multiple myeloma: a single-center experience
Merchionne, F., Procaccio, P., & Dammacco, F. (2008) · Clinical and Experimental Medicine · doi:10.1007/s10238-008-0169-8 · Cited by 10
“It has since been demonstrated that tandem as opposed to single ASCT is more effective in terms of EFS and 7-year OS [ 9 ], although the improvement in OS has not been confirmed in other randomized trials [10].”
BackgroundNivison‐Smith, I., Simpson, J. M., Dodds, A. J., Ma, D. D. F., Szer, J., & Bradstock, K. F. (2013) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.3109/10428194.2013.763396 · Cited by 10
Kyle, R. A., & Dispenzieri, A. A. (2013) · Elsevier eBooks · doi:10.1016/b978-0-7234-3691-1.00094-5 · Cited by 10
Graft-versus-Leukemia Effect of Nonmyeloablative Stem Cell Transplantation
Imamura, M., & Tanaka, J. (2009) · The Korean Journal of Internal Medicine · doi:10.3904/kjim.2009.24.4.287 · Cited by 12
Impact of additional cytoreduction following autologous SCT in multiple myeloma
Kumar, S. K., Dingli, D., Dispenzieri, A. A., Lacy, M. Q., Hayman, S. R., Buadi, F. K., Rajkumar, S. V., Litzow, M. R., & Gertz, M. A. (2008) · Bone Marrow Transplantation · doi:10.1038/bmt.2008.166 · Cited by 10
Autologous stem cell transplantation in multiple myeloma is not dead but alive and well
Martino, M. V., & Morabito, F. (2014) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.2015.988611 · Cited by 10
“Although the studies were performed in the old era, the tandem ASCT approach achieved improvement in OS [27], even though a survival benefit was mainly seen in those patients who failed to achieve at least a VGPR [28,29].”
Villalba, A., González, A. P., Arzuaga‐Méndez, J., Puig, N., Arnao, M., Arguiñano, J.-M., Jimenez, M., Canet, M., Teruel, A. I., Sola, M., et al. (2022) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428194.2022.2123229 · Cited by 10
LeBlanc, R., Claveau, J., Ahmad, I., Delisle, J., Bambace, N. M., Bernard, L., Cohen, S., Kiss, T. L., Lachance, S., Landais, S., et al. (2020) · Clinical Transplantation · doi:10.1111/ctr.14099 · Cited by 10
Tan, D. C. L., Lao, Z., Loh, Y., Ng, H. J. H., Chuah, C. T. H., Wong, G. C., Koh, M., Linn, Y. C., Lim, L. C., Tien, S. L., et al. (2010) · Bone Marrow Transplantation · doi:10.1038/bmt.2010.25 · Cited by 9
The Importance of Complete Response in Outcomes in Myeloma
Nooka, A. K., Kaufman, J. L., & Lonial, S. (2009) · The Cancer Journal · doi:10.1097/ppo.0b013e3181c51cd4 · Cited by 10
Limited feasibility of double transplant in multiple myeloma
Corso, A., Mangiacavalli, S., Barbarano, L., Alessandrino, E. P., Cairoli, R., Morra, E., Lazzarino, M., & on Behalf of the HOST Group (2007) · Cancer · doi:10.1002/cncr.22660 · Cited by 9
Koželj, M., Zver, S., & Zadnik, V. (2013) · Radiology and Oncology · doi:10.2478/raon-2013-0019 · Cited by 9
Yaqub, S., Ballester, G., & Ballester, O. (2013) · Cancer Investigation · doi:10.3109/07357907.2013.840382 · Cited by 9
Jang, J. E., Cheong, J., Kim, S., Cho, H., Suh, C., Lee, H., Eom, H., Yhim, H., Lee, W. S., Min, C., et al. (2015) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.3109/10428194.2015.1102240 · Cited by 11
Treatment of Multiple Myeloma: A Comprehensive Review
Kyle, R. A., & Rajkumar, S. V. (2009) · Clinical Cancer Reviews · doi:10.3816/ccr.2009.n.008 · Cited by 9
Rinn, J. P., Schwella, N., Wollmer, E., Jaques, G., Heinzel‐Gutenbrunner, M., Straßmann, G., Groß, M. W., Movassaghi, K., Neubauer, A., & Ritter, M. (2005) · Annals of Hematology · doi:10.1007/s00277-005-1078-5 · Cited by 9
“mycin 9 mg m day, days 1–4; dexamethasone 40 mg day, days 1–4) [3]; 32 patients received 2–8 cycles of VCAD (VAD + cyclophosphamide 0.”
MethodCook, G., Jackson, G., Morgan, G. J., Russell, N. H., Kirkland, K., Lee, J., Pearce, R., Marks, D. I., Pagliuca, A., & on behalf of the British Society for Blood and Marrow Transplantation (BSBMT) (2010) · Bone Marrow Transplantation · doi:10.1038/bmt.2010.283 · Cited by 9
Hus, I., Mańko, J., Jawniak, D., Jurczyszyn, A. J., Charliński, G., Poniewierska‐Jasak, K., Usnarska‐Zubkiewicz, L., Sawicki, M., Druzd‐Sitek, A., Świderska, A., et al. (2019) · Oncology Letters · doi:10.3892/ol.2019.10929 · Cited by 9
“Tandem ASCT allowed for a further increase of CR, similarly to the previous reports (50,51).”
ResultCorso, A., Mangiacavalli, S., Nosari, A., Castagnola, C., Zappasodi, P., Cafro, A. M., Astori, C., Bonfichi, M., Varettoni, M., Rusconi, C., et al. (2005) · Bone Marrow Transplantation · doi:10.1038/sj.bmt.1705166 · Cited by 9
Changes in multiple myeloma epidemiology in the last thirty years: A single centre experience
Zappasodi, P., Corso, A., Klersy, C., Pica, G.-M., Mangiacavalli, S., Varettoni, M., Rusconi, C., Pascutto, C., & Lazzarino, M. (2006) · European Journal of Cancer · doi:10.1016/j.ejca.2005.09.031 · Cited by 10
“1%), similarly to that reported by Attal with respect to CDT [13].”
BackgroundResultInfluentialCurrent Treatment Strategies for Multiple Myeloma
Thomas, S. K., & Alexanian, R. (2007) · Clinical Lymphoma & Myeloma · doi:10.3816/clm.2007.s.014 · Cited by 9
Case 38-2004: A 40-Year-Old Man with a Large Tumor of the Skull
Richardson, P. G. G., Kassarjian, A., & Wen, J. (2004) · New England Journal of Medicine · doi:10.1056/nejmcpc049029 · Cited by 10
Evolving Role of Stem Cell Transplantation in Multiple Myeloma
Harousseau, J., & Moreau, P. (2005) · Clinical Lymphoma & Myeloma · doi:10.3816/clm.2005.n.034 · Cited by 10
Self-citationPérez‐Simón, J. A., Caballero, D. M., Mateos, M., & Miguel, J. F. S. (2004) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428190410001667686 · Cited by 9
“survival curve justifies the development of alternatives [18].”
BackgroundResultCellular immunotherapy for plasma cell myeloma
Garfall, A. L., Vogl, D. T., Weiss, B. M., & Stadtmauer, E. A. (2013) · Bone Marrow Transplantation · doi:10.1038/bmt.2013.54 · Cited by 8
Salit, R. B., & Bishop, M. R. (2011) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2011.03.010 · Cited by 8
Hematopoietic Stem Cell Transplantation in Multiple Myeloma in the Era of Novel Therapies
Al‐Anazi, K. A. (2019) · IntechOpen eBooks · doi:10.5772/intechopen.79999 · Cited by 9
Chen, Y., Fogel, L., Sun, A. Y.-E., Yang, C., Patel, R. P., Chang, W.-C., Chen, P., Jhou, H., Chen, Y., Dai, M., et al. (2024) · Diagnostics · doi:10.3390/diagnostics14101030 · Cited by 11
“Ten studies, including seven randomized controlled trials [9,10,14,16,20–22] and three retrospective cohort studies [6,19,23], reported data on PFS.”
InfluentialIgarashi, N., Chou, T., Hirose, T., Imai, Y., & Ishiguro, T. (2010) · International Journal of Hematology · doi:10.1007/s12185-010-0690-x · Cited by 8
“In previous randomized trials, HDCT with ASCT has been reported to be more effective for achieving or consolidating CR compared with conventional chemotherapies [5, 6]. Furthermore, in patients who failed to achieve VGPR within 3 months after undergoing a single transplantation, double transplantation significantly im…”
ResultOptimal maintenance and consolidation therapy for multiple myeloma in actual clinical practice
Lee, H. S., & Min, C. (2016) · The Korean Journal of Internal Medicine · doi:10.3904/kjim.2016.110 · Cited by 11
“[6] confirmed the clinical impact of consolidation therapy using tandem ASCT in patients with MM.”
ResultAl‐Ani, F., & Louzada, M. (2017) · European Journal Of Haematology · doi:10.1111/ejh.12961 · Cited by 8
Multiple Myeloma and Related Disorders
Rajkumar, S. V., & Dispenzieri, A. A. (2014) · Elsevier eBooks · doi:10.1016/b978-1-4557-2865-7.00104-1 · Cited by 9
Venner, C. P., Duggan, P. R., Song, K., Reece, D. E., Sharma, S., Su, J., Jimenez-Zepeda, V. H., McCurdy, A. B. R., Louzada, M., Mian, H. S., et al. (2024) · Transplantation and Cellular Therapy · doi:10.1016/j.jtct.2024.06.030 · Cited by 9
Migkou, M., Kastritis, E., Ρούσσου, Μ., Gkotzamanidou, M. A., Gavriatopoulou, M., Nikitas, N., Mparmparousi, D., Matsouka, C., Gika, D., Terpos, E., et al. (2011) · European Journal Of Haematology · doi:10.1111/j.1600-0609.2011.01659.x · Cited by 8
“Furthermore, the prognostic importance of achievement of VGPR has been established from data coming from patients who had undergone HDT and were younger and fitter (10, 22, 23), while our study included unselected elderly patients.”
ResultRole of autologous bone marrow transplant in multiple myeloma
Blanes, M., & de la Rubia, J. (2012) · Current Opinion in Oncology · doi:10.1097/cco.0b013e328358f686 · Cited by 10
Kalff, A., Kennedy, N., Smiley, A., Prince, H. M., Roberts, A. W., Bradstock, K. F., Lourenço, R. D. A., Frampton, C. M., & Spencer, A. G. (2014) · The Lancet Haematology · doi:10.1016/s2352-3026(14)00022-2 · Cited by 8
Byrne, M. T., Salmasinia, D., Leather, H. L., Cogle, C. R., Davis, A. L., Hsu, J. W., Wiggins, L., Chang, M. N., An, Q., Wingard, J. R., et al. (2014) · Clinical Medicine Insights Oncology · doi:10.4137/cmo.s16835 · Cited by 10
Sutlu (2009) · Oncology Reports · doi:10.3892/or_00000416 · Cited by 8
Role of Allogeneic Stem Cell Transplantation in Multiple Myeloma
Bruno, B., Giaccone, L., Sorasio, R., & Boccadoro, M. (2009) · Seminars in Hematology · doi:10.1053/j.seminhematol.2009.02.001 · Cited by 12
Metadata
- Authors
- Attal, M., Harousseau, J.-L., Facon, T., Guilhot, F., Doyen, C., Fuzibet, J.-G., Monconduit, M., Hulin, C., Caillot, D., Bouabdallah, R., Voillat, L., Sotto, J.-J., Grosbois, B., & Bataille, R.
- Affiliations
- Hôpital Purpan (FR)
- Hôpital Claude Huriez (FR)
- Centre Hospitalier Universitaire de Poitiers (FR)
- Centre Hospitalier Universitaire de Nice (FR)
- Centre Henri Becquerel (FR)
- Centre Hospitalier Régional et Universitaire de Nancy (FR)
- CHU Dijon Bourgogne (FR)
- Centre Hospitalier Universitaire de Besançon (FR)
- Hôpital Albert Michallon (FR)
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2003-12-25
- Volume
- 349
- Issue
- 26
- Pages
- 2495-2502
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W1982499121
- Cited by
- 984
- References
- 16
- Citations by year
- 2026: 3 · 2025: 13 · 2024: 18 · 2023: 14 · 2022: 22 · 2021: 20 · 2020: 33 · 2019: 18 · 2018: 35 · 2017: 28 · 2016: 24 · 2015: 37 · 2014: 38 · 2013: 53 · 2012: 42
- FWCI
- 34.51
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Digital Access to Libraries (submittedVersion)
- Topics
- Health Sciences › Medicine › Hematology › Multiple Myeloma Research and Treatments
- Health Sciences › Medicine › Hematology › Hematopoietic Stem Cell Transplantation
- Health Sciences › Medicine › Clinical Neurology › Multiple Sclerosis Research Studies
- Keywords
- multiple myeloma, autologous stem cell transplantation, high-dose chemotherapy, overall survival, event-free survival, very good partial response, beta2-microglobulin, lactate dehydrogenase, prognostic factors
- MeSH terms
- Antineoplastic Combined Chemotherapy Protocols, Combined Modality Therapy, Dexamethasone, Doxorubicin, Female, Humans, Male, Middle Aged, Multiple Myeloma, Neoplasm Staging, Prognosis, Transplantation, Autologous, Vincristine, Survival Rate, Multivariate Analysis, Hematopoietic Stem Cell Transplantation, Disease-Free Survival, Transplantation Conditioning
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.